Methods and compositions for reducing adipocyte numbers

A method for reducing a fat deposit in vivo, the method comprising injecting into an interstitial space adjacent to the fat deposit an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, the fat deposit is a subcutaneous fat deposit or a visceral fat deposit, and the effective amount of the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.

A method for reducing a subcutaneous fat deposit in vivo, the method comprising injecting into or adjacent to the subcutaneous fat deposit an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and the effective amount of the composition reduces a number of adipocytes in the subcutaneous fat deposit by 5% to 90%.

A method for treating steatoblepharon in a subject, the method comprising identifying a subject in need of treatment for steatoblepharon and injecting into a fat deposit in an eyelid of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and the effective amount of the composition reduces a number of adipocytes in the fat deposit by 5% to 90%.

A method for treating proptosis in a subject, the method comprising identifying a subject in need of treatment for proptosis and injecting into an intraconal space of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and the effective amount of the composition reduces a number of adipocytes in the intraconal space by at least 35%.

A method for treating obstructive sleep apnea associated with an excess upper airway fat in a subject, the method comprising identifying a subject in need of treatment for obstructive sleep apnea and injecting into an upper airway fat deposit of the subject an effective amount of a composition of latanoprost encapsulated in a liposome, wherein the liposome is formed solely of egg phosphatidylcholine or palmitoyloleoyl phosphatidylcholine, a concentration of latanoprost in the composition is 0.5 mg/mL to 3.0 mg/mL, and the effective amount of the composition reduces a number of adipocytes in the upper airway fat deposit by 5% to 90%.